Scribe Therapeutics

Scribe Therapeutics is a clinical-stage biotechnology company founded in 2018 and headquartered in Alameda, California, engineering CRISPR-based genetic medicines through its proprietary "CRISPR by Design" platform. Co-founded by molecular engineers Benjamin Oakes, Brett Staahl, and David Savage alongside CRISPR co-inventor Jennifer Doudna, the company builds highly engineered CasX-derived enzymes — including its X-Editing (XE) molecules for precise gene editing and ELXR epigenetic long-term X-repressor technology for durable gene silencing without altering the underlying DNA sequence. Scribe focuses initially on cardiometabolic disease, the leading cause of death globally, and expands into areas such as sickle cell disease and neurological conditions through strategic pharmaceutical partnerships. The company is backed by a16z and Menlo Ventures and was surfaced to the API Evangelist network as a venture portfolio company. Scribe Therapeutics is a therapeutics and drug-discovery company and does not currently publish a public developer API, SDK, or documented API surface.

Scribe Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, CRISPR, Gene Editing, and Genetic Medicine.

Scribe Therapeutics’ developer surface includes engineering blog, support, and 7 more developer resources.

🌐 Visit website 📡 Source on GitHub
11.9/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotechnologyCRISPRGene EditingGenetic MedicineTherapeuticsLife SciencesDrug Discovery

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 11.9/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 1.3 / 20
Commercial Clarity 2.1 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/scribe-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Scribe Therapeutics Domain Security

TLSv1.3 · HSTS · DNSSEC · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support
Support

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy

Company 6

The organization behind the API

Website
Website
 About
About
 Blog
Blog
 Careers
Careers
 LinkedIn
LinkedIn
 Twitter
Twitter

Source (apis.yml)

apis.yml Raw ↑ 
aid: scribe-therapeutics
name: Scribe Therapeutics
description: Scribe Therapeutics is a clinical-stage biotechnology company founded in 2018 and headquartered in Alameda, California,
  engineering CRISPR-based genetic medicines through its proprietary "CRISPR by Design" platform. Co-founded by molecular
  engineers Benjamin Oakes, Brett Staahl, and David Savage alongside CRISPR co-inventor Jennifer Doudna, the company builds
  highly engineered CasX-derived enzymes — including its X-Editing (XE) molecules for precise gene editing and ELXR epigenetic
  long-term X-repressor technology for durable gene silencing without altering the underlying DNA sequence. Scribe focuses
  initially on cardiometabolic disease, the leading cause of death globally, and expands into areas such as sickle cell disease
  and neurological conditions through strategic pharmaceutical partnerships. The company is backed by a16z and Menlo Ventures
  and was surfaced to the API Evangelist network as a venture portfolio company. Scribe Therapeutics is a therapeutics and
  drug-discovery company and does not currently publish a public developer API, SDK, or documented API surface.
url: https://raw.githubusercontent.com/api-evangelist/scribe-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- a16z
- menlo-ventures
x-tier: stub
x-tier-reason: portfolio-lead
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-21'
image: https://www.scribetx.com/favicon.ico
tags:
- Company
- Biotechnology
- CRISPR
- Gene Editing
- Genetic Medicine
- Therapeutics
- Life Sciences
- Drug Discovery
apis: []
common:
- type: DomainSecurity
  url: security/scribe-therapeutics-domain-security.yml
- type: Website
  url: https://www.scribetx.com/
- type: About
  url: https://www.scribetx.com/about
- type: Blog
  url: https://www.scribetx.com/news
- type: Support
  url: https://www.scribetx.com/contact
- type: Careers
  url: https://www.scribetx.com/careers
- type: PrivacyPolicy
  url: https://www.scribetx.com/privacy
- type: LinkedIn
  url: https://www.linkedin.com/company/scribe-therapeutics/
- type: Twitter
  url: https://x.com/scribetx
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-21'
  status: minimal
  artifacts_added: 1
  pass: local-v1